Pfizer (PFE) Tops Q2 EPS by 14c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
July 31, 2024 5:20 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Pfizer (NYSE: PFE) to $34.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance on the day (+2% vs. flat XLV) appears warranted in our view given solid 2Q results... More
Pfizer hikes full-year outlook as Q2 results top estimates; shares up
July 30, 2024 6:58 AM EDT(Updated - July 30, 2024 9:48 AM EDT)
Pfizer (NYSE: PFE) shares rose more than 1% at the start of trading on Tuesday after the drugmaker hiked full-year guidance and reported better-than-expected Q2 earnings and revenue.
The companys earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion.
Pfizer reported adjusted research and development expenses of $2.67 billion for the... More
